Catalonia Life Sciences Report 2011

Size: px
Start display at page:

Download "Catalonia Life Sciences Report 2011"

Transcription

1 Catalonia Life Sciences Report 2011

2 2

3 Contents Chapter 1 Preface 4 Chapter 2 Scope of the report 8 Chapter 3 Introduction to the Catalonia Life Sciences Sector 10 Chapter 4 National and International Benchmarking 30 Chapter 5 R&D in Catalonia 36 Chapter 6 Financing 44 Appendix Selection of Catalonia Research Centers and Large Facilities 53 Appendix Scientific & Technology Parks 54 Glossary of terms 55 3

4 The commitment to innovation should be the best corporate insurance to overcome the crisis Chapter 1 4 Biocat Catalonia Lifesciences

5 Preface Silvia Ondategui-Parra, MD, MPH, MSc, PhD Partner - Mediterranean Life Sciences Leader / Global Market Access Leader An increasingly demanding market In the last years the biotechnology market has been constantly increasing at the expense of traditional chemistry. Additionally, the growth of biotechnology has become the ultimate pillar for international pharmaceutical research to spread. In turn, small biotechs aspiration is for big pharma companies to adopt their molecules as soon as possible, since development is expensive and it is impossible for them to face future on their own. This objective seems more elusive with the crisis: labs do not want to take risks and prefer to wait until success is ensured. Indeed, biotechnology is the great hope and, in figures, around 200 compounds in the late stages of research could generate 150,000 millions a year. But good intentions are not enough, and in this increasingly demanding market an efficient strategy is called for. The present is asking us to be more dynamic, to take new business paths and lean on partners to achieve goals. In Catalonia and at global level, investments in innovation are growing exponentially in order to satisfy ever more informed patients, with growing decision-making power, and a health system which is increasingly focused on improving its management cost. In this regard, the role of the companies in this industry goes far beyond mere development and manufacture of products. This evolution is being prompted by fast developments in information technology, lack of solvency and difficulties in health system sustainability at global level. Opportunities generated in this new scenario are attracting a growing number of new non-traditional players in the healthcare area. At Catalan level, biotechnology is a powerful although industry. On the other hand the pharma industry, which represent one of the most profit-generating industry is well established in Catalonia. That is why synergies between Biotech and pharma companies should be deeply fostered in order to cooperate in joint projects for advancing on biotechnological research and innovation. In order to carry out these developments, Governments and companies should opt for business models that are better managed, more efficient and whose future feasibility is guaranteed. They should not avoid the challenges laying ahead within an ever-changing environment deeply affected by the financial crisis. In conclusion, we are aware that the commitment to innovation should be the best corporate insurance to overcome the crisis. Prospects for the coming years are not good. Traditionally, the pharma industry links its R&D investments to turnover evolution, even under the current scenario where companies turnover is decreasing. Catalonia Life Sciences Report

6 Catalonia has 21% of all the companies of the Spanish biotechnology sector. The total turnover of the sector in the BioRegion totals more than 15,000 Million 6 Preface

7 Montserrat Vendrell CEO, Biocat Accelerating opportunities for the BioRegion of Catalonia Over the past 10 years, Catalonia has seen an unprecedented level of growth in its research capacities, putting it among the most dynamic and productive regions in Europe in terms of knowledge generation. While Catalonia accounts for 1.5 % of Europe s population, it contributes to 1.69 % of its GDP, 2.98 % of scientific production and boasts 3.48 % of ERC grants (2011), two fold the European average, only after Switzerland, Israel, UK and Belgium. Furthermore, joint efforts of both the Catalan and Spanish governments, have allowed for the construction of key scientific facilities such as the National Genome Analysis Center (CNAG), the Alba-CELLS Synchrotron, or the Barcelona Supercomputer Mare Nostrum. Catalonia has 80 bioscience research centers some of which are international benchmarks in genomics (CRG), photonics (ICFO) or oncology (IRB). Alongside this scientific development, the business sector has experienced unstoppable growth since 2000 at a rate of 15% to 30% per year and is now made up of 480 companies, including biotechnology, pharmaceutical, medical technology and sectorservices firms. This business activity is concentrated (85% of the organizations in the sector) mainly around Barcelona, which is also home to most of the 20 science parks in the region. Although the majority of these companies (65%) are SMEs and despite the adverse economic conditions they have had to deal with over the past two years, the comparative analysis Biocat carried out for the 2009 and 2011 fiscal years shows a positive evolution both in economic terms and in research capacities. Catalonia has 21% of all the companies in the Spanish biotechnology sector. The total turnover of the sector in the BioRegion totals more than 15,000 millions, with more than 2,300 millions in capitalization, which more importantly tripled in the time period. The increase in investment 92% of which is private has been accompanied by a significant increase in research capacities in the clinical phases and has allowed these companies to have a pipeline of 270 new therapeutic products and more than 300 new medical technologies. Biocat was created in 2006 by the Catalan Government, the Barcelona City Council, universities, hospitals, research centers and companies to boost a strong BioRegion, competitive at international level. This report sums up the assets this concerted public/private effort has achieved at present, which have made Catalonia a benchmark in clinical innovation and advanced therapies with a number of top-notch projects in the pipeline at our companies and research centers. New diagnostic tools to detect cancer or a predisposition to cardiovascular disease, genetic tests to discover a patient s sensitivity to specific medicines, a new vaccine for tuberculosis and one for malaria in the final clinical phases, new probiotic foods, agrifood pathogen detectors, surgical biomaterials, new biological or nanotechnological methods for drug encapsulation and delivery, new components for the cosmetics industry. These are just some examples of the products Catalan biotechnology firms have already put on the market or are developing at the moment. They are also an example of the sector s potential, which is the result of the ongoing effort Catalonia has made over the past 15 years to drive research and a knowledge-based economy. Naturally, in order to make the most of its potential, Catalonia must collaborate with other clusters such as Massachusetts, Maryland, California and more. We hope this report will be a tool to drive this cooperation in order to fuel a sector that is key to tackling the large-scale challenges currently facing the world while, at the same time, guaranteeing economic growth and social wellbeing. Catalonia Life Sciences Report

8 Executive Summary 2Chapter 2 8 Catalonia Life Sciences Report 2011

9 Scope of the report Catalonia is the region that makes the biggest contribution to the Spanish economy, producing the 18.6% of the country s GDP. Its traditional business dynamism and its entrepreneurship culture, along with the political will of the autonomous government, have allowed the development, during the last ten years, of a strong R&D system and a huge number of innovative companies in knowledgebased sectors as life sciences. Although the negative impact of the global economic crisis on R&D investments, both public and private, the biotechnology industry in Catalonia is still on an upward trend and indicators show positive evolution. The purpose of the Catalan edition of the Life Sciences Report issued by Ernst & Young, in collaboration with Biocat*, is to offer an in-depth analysis of the industry: on one hand, to show the main figures, analyzing the current status of biotechnology, biomedicine and medical technologies in Catalonia, within a global economic instability environment; on the other hand, to see the evolution of the industry in recent years and identify new challenges, strategies and future prospects. In the preparation of this report, we have taken into account the content of Biocat Report 2011, based on data gathered from an extensive survey sent to both public and private entities that perform their work and research activities within biotechnology, biomedicine and medical technology, which together constitute Catalonia s BioRegion. The survey was sent out in December 2010 to 435 research groups and to 450 companies in the BioRegion, 49.5% of which responded. This high level of survey participation (438 organizations) has allowed a consistent analysis of Catalan life sciences companies and research institutions, including some estimates for the sector as a whole. All other consulted sources are explicitly identified where appropriate. Thus, the final objective is to highlight the relevance of the biotechnology, biomedicine and medical technologies in Catalonia that could become the driving force of Catalan economy and innovation, identifying the strengths, pending challenges and the appropriateness of establishing long-term policies. *Biocat is the entity responsible for boosting and fostering the BioRegion in Catalonia. For further information please visit Catalonia Life Sciences Report

10 3Chapter 3 10 Catalonia Life Sciences Report 2011

11 Introduction to the Catalonia Life Sciences Sector With more than 1,100 registered entities, including research institutions and companies, Catalonia is the leading biocluster in Spain and a reference hub in Southern Europe. The steady increase of the number of companies and several initiatives to foster research and innovation prove the BioRegion s dynamism. Figure 3.1 Biotechnology and biomedicine subsectors The entities that constitute Catalonia Life Sciences sector are grouped in one of the major biotechnological clusters in Spain: the BioRegion. The BioRegion is Catalonia s biotechnology, biomedicine and medical technologies cluster. It comprises biotechnology, pharma and medical technology companies, as well as universities, hospitals and research centers. It also includes structures and networks supporting transfer of knowledge and innovation. According to data gathered in the Biocat directory in June 2011 the BioRegion consists of 1,156 entities, which cover strongly interconnected activities (figure 3.1). As shown in figure 3.2, the main group in Biocat directory is integrated by companies (481) and it also includes 80 research centers on life sciences, 15 hospitals and 12 universities. These three types of organizations account for 435 research groups (56.1% in universities, 33% in research centers, and 7.4% in hospitals) that are also registered in the Biocat directory. Green Biotech Green biotechnology deals with the use of environmentally-friendly solutions as an alternative to traditional agriculture, horticulture, and animal breeding processes. An example is the designing of transgenic plants that are modified for improved flavor, for increased resistance to pests and diseases, or for enhanced growth in adverse weather conditions White Biotech White biotechnology, or industrial biotechnology, as it is also known, refers to the use of living cells and/or their enzymes to create industrial products that are more easily degradable, require less energy, create less waste during production and sometimes perform better than products created using traditional chemical processes Red Biotech Red biotechnology refers to the use of organisms for the improvement of medical processes. It includes the designing of organisms to manufacture pharmaceutical products like antibiotics and vaccines, the engineering of genetic cures through genomic manipulation, and its use in forensics through DNA profiling Biomedicine Pharma activites Pharma develops, produces, and markets drugs licensed for use as medications. Pharmaceutical companies are allowed to deal in generic and/or brand medications and medical devices. They are subject to a variety of laws and regulations regarding the patenting, testing and ensuring safety and efficacy and marketing of drugs Medical technology Medical Technology encompasses a wide range of healthcare products and is used to diagnose, monitor or treat diseases or medical conditions affecting humans. Such technologies (applications of medical science) are intended to improve the quality of healthcare delivered through earlier diagnosis, less invasive treatment options and reductions in hospital stays and rehabilitation times. Recent advances in medical technology have also focused on cost reduction Catalonia Life Sciences Report

12 Catalonia s BioRegion is one of the most dynamic bioclusters in Europe Catalonia s BioRegion is one of the more dynamic bioclusters in Europe. It has a majority of young and small start-up between its companies but it has also an increasing capacity of research and manufacturing of innovative products both in the private sector and in public institutions. Catalonia also outstands among other bioregions for the creation of new biotech companies, with a steady increase of 15% per year in 2010 and Other European clusters (figure 3.3) have remained stable in size or are stagnated economically and financially in recent years. Others, such as BioTOP Berlin or Oxford biocluster (OBN), have also shown notable growth in the last two years. Both cases are linked to the traditional dynamism of the industry in these areas and the economic power of both regions. Figure 3.2 Distribution of different types of organizations in the BioRegion (2011) Research groups University Research Center 7% 4% Hospital 33% Other 56% Company 2% 2% 1% 1% 11% 3% 4% 8% 68% Technology infraestructure & Scientific Service Entity of support Scientific - Technologic Park Research Center Hospital University Large infraestructure Technologic center 12 Catalonia Life Sciences Report 2011

13 Figure 3.3 Main European clusters Taking into account the pressure of the economic context and the internal maturation process of BioRegion, it is likely that the set-up of new companies will tend to stabilize, while other indicators related to consolidation stages are expected to increase, i.e. the companies turnover, volume of hired personnel, internationalization or the number of new products launched into the market. Although Chapter 5 offers a comprehensive panorama about R&D in Catalonia it is worth mentioning in this introduction some new initiatives and processes that have reinforced the capacities of the BioRegion both in research and in technology transfer. Uppsala Bio Health research centers In March 2011, Sant Pau Institute of Biomedical Research (IIB Sant Pau) was accredited by Spanish Science Ministry (through the Carlos III Health Institute, ISCIII) as a Health Research Institute. It was the fifth Catalan hospital research center receiving this recognition, that only 16 hospital institutes all over Spain have. IDIBAPS (August Pi i Sunyer Biomedical Research Institute), linked to Hospital Clinic; IDIBELL (Bellvitge Biomedical Research Institute), from Hospital de Bellvitge; VHIR (Vall d Hebron Research Institute), related with Hospital Vall d Hebron; and IGTP (Health Sciences Research Institute of the Germans Trias i Pujol Foundation), from Hospital Germans Trias I Pujol, all of them placed in Barcelona area, were the first four accredited institutes in Spain in The objective of ISCIII initiative is to promote hospitals as research centers, providing the necessary equipment to create healthcare and teaching environments and high-quality research. Amsterdam BioMed OBN - Oxford One Nucleus Cambridge/London BioWin - Belgium GIP Genopole - Paris BioValley - Alsace Lyonbiopole Biocat - BioRegion of Catalonia BioPMed - Torino Stockholm Science City Medicon Valley Denmark/Sweden BioTOP Berlin-Bradenburg BioM - Munich LISA - Vienna These institutes are a key piece of the Catalan research system that reinforces the region s capacities on translational research. Catalonia Life Sciences Report

14 Executive Summary Major infrastructures From 2005 to 2011, three major scientific infrastructures have been established in Catalonia, thanks to political and economic regional efforts. All of them are reference centers no only in Spain, but at European level. The Alba Synchrotron is operative since There are 49 synchrotrons in the world and Alba is the first installation of its kind in Spain. 201 million euros have been invested in this project since 2003, financed fifty-fifty by the Catalan and Spanish Governments. The Alba Synchrotron can have up to 33 beamlines and receive more than 1,000 researchers every year. The National Centre for Genomic Analysis (CNAG) was created in 2009 with the support of the Spanish and Catalan Governments and started operating in March CNAG s purpose is to carry out large scale DNA sequencing projects. The centre is located within Barcelona Science Park and on 1,200 square meters. Its sequencing power is one of the largest in Europe. The Barcelona Supercomputing Center (BSC), Spain s National Supercomputing Center, plays host to the Mare Nostrum supercomputer, one of the most powerful in Europe. BSC provides High Performance Computing (HPC) services for Spanish researchers and is a member of PRACE (Partnership for Advanced Computing in Europe), a joint initiative of 24 countries that allows to offer pan- European HPC services to academia and industry. Campuses of excellence Campus of excellence is an initiative of the former Spanish Ministry of Education to foster research, technology transfer and innovation around university campuses, and acknowledges joint private-public efforts to achieve these goals. Catalonia has six campuses of excellence. CoE promote strategic links and interactions between research centers, science & technology parks, production environments and other players, in order to develop ecosystems that link education, knowledge, research and innovation. The six Catalan campuses of excellence received 41 million euros out of 182 invested by Spanish Government in this initiative in 2009 and The six existing Catalan campuses are: BKC - Barcelona Knowledge Campus of Universitat de Barcelona (UB) and Universitat Politècnica de Catalunya (UPC) UAB CEI: Promoting knowledge, encouraging innovation of Universitat Autònoma de Barcelona (UAB) UPC Energy Campus Energy for Excellence of Universitat Politècnica de Catalunya (UPC) HUBc - Health Universitat de Barcelona Campus of Universitat de Barcelona (UB) Icaria CEI of Universitat Pompeu Fabra (UPF) CEICS - Campus of International Excellence Southern Catalonia of Universitat Rovira i Virgili (URV) 14 Catalonia Life Sciences Report 2011

15 Focus on Catalonia Life Sciences Companies The Catalan business network has a significant number of start-ups, SMEs and consolidated pharma companies. Innovation and internationalization are at the core of their business strategy, being biomedicine the main field of activity. Additionally, Catalan biotech companies are responsible for 85% of registered patents. Despite global crisis and investment difficulties, Catalonia continues to be the Spanish leader in innovation related to the set-up of new biotechnology companies. 11 biotechnology companies were created in Catalonia only in 2010, representing 23% of all the new companies established in Spain. Most Catalan biotechnology companies have been created after 2000, which accounts for the big boom seen during the first decade of the 21st century. The establishment of incubators and science parks, along with government grants to helps creation of companies (CIDEM- ACC1Ó), have contributed to this growth. Figure 3.4 Establishment year of the BioRegion companies The increase in new biotech companies in Catalonia has remained constant during the last years, with about new firms per year (figure 3.4).The figures of 2011 (12 new companies) show that entrepreneurs in Catalonia continue to be active despite the economic crisis and the difficult context. 77.4% of new companies in the BioRegion arise from private initiatives, either as start-ups from another company or as a particular entrepreneur action. However, if we only consider companies engaged in research and exclude service or support companies, the weight of public initiative in the set-up of company increases significantly (figure 3.5). 84.1% of the companies are of Catalan origin while 15.9% are subsidiaries of international companies (figure 3.6). It should be highlighted that 58% of the companies in the BioRegion undertake R&D activities while the rest are services providers. Most of the figures in the following sections distinguish the performance of R&D companies from the rest. Figure 3.5 Origin of the company according to the driving entity R&D Companies 19.1% All Companies 1.7% 5% 5.8% 1% 4.3% 3.4% 13.9% Company University Research center Hospital Others 68.6% 77.4% 18 Number of companies R&D companies Establishment year All companies New companies that did not participate in the survey Figure 3.6 Total number of Catalan origin companies 15.9% Companies created in Catalonia Subsidiary companies 84.1% Catalonia Life Sciences Report

16 Catalan Life Sciences industry employs 22,000 people, half of which work on R&D activities Activity environment Barcelona and its metropolitan area concentrate 85% of life sciences companies located in Catalonia. However, as shown in figure 3.7, there are research companies all over the BioRegion. 81% of the companies have a single work center and they choose to set up mainly in an industrial environment industrial parks or technology centers, where 44% of the companies are located and in urban areas (34%), followed by science and technology parks (29%). Most of R&D start-ups are located in knowledge-driven environments: up to 38.8% in science and technology parks and 17% in universities and hospitals. Chapter 5 of this report highlights the importance of parks as a meeting point for research and business and its role in the creation and consolidation of the BioRegion. Figure 3.7 Geographic distribution of the companies in the BioRegion Red biotech White biotech Green biotech Medical technologies Ripoll Manlleu Bigues i Riells Palau Solità i Plegamans Sentmenat Lliça d Amunt Girona Alpicat Masquefa Sant Feliu de Llobregat Abrera Cervera Rubí Santpedor Bellaterra Sabadel Terrassa Sant Quintí de Mediona Sant Just Desvern Barberà del Vallès Les Franqueses del Vallès Llinars del Vallès Sant Pol de Mar Granollers Parets del Vallès Mollet del Vallès Constantí Valls Villanova i la Geltrú Gavà El Masnou Santa Perpètua de la Mogoda Amposta Castellvell del Camp Reus Tarragona Castelldefels Sant Joan Despí Sant Boi de Llobregat Hospitalet de Llobregat Ripollet Badalona Montcada i Reixat Cornellà de Llobregat Esplugues de Llobregat Cerdanyola del Vallès Sant Cugat del Vallès Barcelona 16 Catalonia Life Sciences Report 2011

17 Figure 3.8 Main activities of the BioRegion companies Number of companies R&D+i Production Marketing / Sales Services 0 Scie-Tech consultancy CRO Equipment suppliers Training Business development CMO Quality & regulatory Industrial property Financing/investors Main activities Figure 3.9 BioRegion companies business model 25.5% 6.7% Dual model company Product company Technology company N/A 31.3% 36.5% Business model Nearly half of companies (48.8%) have activities along two or three different phases of the value chain. This is a highly technological and focused industry, with great added value: 58.2% of the companies are engaged in R&D activities and 40.3% in manufacturing. Only 18.2% of R&D companies carry out activities throughout the whole value chain, from discovery to market. 50% of the companies conduct marketing and sales activities and most of them (61.5%) choose to use their own marketing channels, whereas 46.2% sign distribution agreements. Many companies, though, combine both marketing options, depending on the product or the market. The percentage of service companies has significantly increased, whether they render those services as a core activity or to supplement their R&D activities. This increase is partly due to the fact that the market has grown as a result of the outsourcing trend. The different activities of service companies are detailed in figure 3.8. The companies in the BioRegion choose mainly a dual business model, which combines own product development and services offered to third parties (figure 3.9). This dual model stands as the best option, as the search for liquidity becomes a priority for the companies in a difficult financial environment. Catalonia Life Sciences Report

18 Activity fields Biomedicine is the main area of activity of the Bioregion companies. As shown in figure 3.10, 47.1% of firms work in red biotech (58.7% of R&D companies) and 52.4% work in medical technologies (45.5% of R&D segment). The figures are smaller for green and white biotech, even though 2010 Biocat s survey showed higher companies performance in these subsectors compared to % of all companies work in green biotech (28.1% of R&D companies) while they were only 16.7% in On the other hand, 47% of R&D companies work in white biotech, but this subsector occupies only 27.4% of the whole business network, with very few service companies working in this field. In any case, the figure has increased substantially since 2009 when white biotech occupied 17.6% of companies in the BioRegion. Regarding application areas (figure 3.11) it is interesting to highlight that 18% of all companies are engaged in cosmetics, that is a significant activity for small pharma companies, especially in the OTC and dermopharmacy lines. Most companies, especially those engaged in offering services and advisory activities, are working in different application areas of diverse subsectors of activity. Only 31% of companies focus on a single application area. Figure 3.10 Subsectors of activity of the BioRegion companies Green biotech R&D companies All companies White biotech Medtech Red biotech 0% 50% 100% 18 Catalonia Life Sciences Report 2011

19 1. Biomedicine Human health accounts for 73.3% of the activity of companies engaged in biomedicine, whereas 16.7% of them focus on animal health. These percentages remain quite the same when talking about R&D companies: 76% work on human health and 19.8% on animal health. Human health predominance in the Catalan biotech industry is due to interaction of several factors: an excellent network of hospital research institutes, which carry out outstanding translational research; public investments in recent years in these fields; and business and research activities of several pharma companies with notable weight in the industry. Even so, the biomedicine subsector focused on animal health offers great potential to Catalonia. A good example of this is that in 2011 Pfizer moved to Catalonia a substantial part of its animal health research activities to a plant located in Olot (Girona). Business efforts put into biomedical research are mainly aimed at developing new therapeutic and biological products (66.3%), medical devices (46.3%), in vitro diagnostic (32.6%) and, to a lesser degree, electromedicine (e-health) and diagnostic imaging (14.7% each), as shown in figure Main therapeutic areas of R&D companies are central nervous system (CNS) and oncology (ranging close to 27%), followed by cardiovascular diseases, immunology and dermatology (close to 19%) and infectious diseases (16.5%) mainly done by start-ups which could cover a niche often discarded by big corporations. Some differences were recorded when comparing R&D to commercialization activities. In this latter, cardiovascular, oncology and dermatology continue to be leading areas, whereas CNS decreases to 13%. (figure 3.12). Figure 3.11 Application areas in subsectors of activity 70% Biomedicine Percentage of Companies 60% 50% 40% 30% 20% 10% Green biotech White biotech Others 0% Pharma or biological therapies Medical devices In vitro diagnostic Electromedicine Diagnostic imaging R&D companies All companies Nutrition Environment Agricultural R&D companies All companies Bioprocesses Biomaterials Fine chemical R&D companies All companies Biotreatments Cosmetics Bioinformatics Areas of activity R&D companies All companies Catalonia Life Sciences Report

20 Figure 3.12 Therapeutic areas in research and commercialization of the BioRegion companies R&D Companies 35 Number of Companies R&D Commercialization 5 0 Central Nervous System Oncology Cardiovascular System Immunology Dermatology Infectious diseases Inflammatory diseases Gastrointestinal System Respiratory System Obstetrics and Gynecology Ophthalmology Trauma and locomotor system Hematology Genitourinary System Endocrinology Others Therapeutic areas All Companies 35 Commercialization 30 Number of Companies Central Nervous System Oncology Cardiovascular System Immunology Dermatology Infectious diseases Inflammatory diseases Gastrointestinal System Respiratory System Obstetrics and Gynecology Ophthalmology Therapeutic areas Trauma and locomotor system Hematology Genitourinary System Endocrinology Others 20 Catalonia Life Sciences Report 2011

The Commercialization of Technology Concepts into Medical Products

The Commercialization of Technology Concepts into Medical Products The Commercialization of Technology Concepts into Medical Products Kevin J. Scanlon, Ph.D. New Zealand 2006 International BioScience Overview Pharmaceutical Industry Biotechnology Startups Investment Community

More information

Master s Programs UNIVERSITY OF CATALONIA

Master s Programs UNIVERSITY OF CATALONIA BARCELONA CATALONIA Master s Programs UNIVERSITY OF CATALONIA As an international student, are you looking for a high-quality academic education? At Catalan universities you are guaranteed first-class

More information

Join our scientific talent community

Join our scientific talent community Join our scientific talent community There has never been a better time to be a part of Janssen Research & Development. We are at the forefront of healthcare leading, evolving and transforming it into

More information

2014 Report: biotechnologies in the Italian pharmaceutical sector

2014 Report: biotechnologies in the Italian pharmaceutical sector 2014 Report: biotechnologies in the Italian pharmaceutical sector In collaboration with Assobiotec Executive summary Executive summary Executive summary Biotechnologies have always influenced all spheres

More information

Indian Biotechnology Sector Overview

Indian Biotechnology Sector Overview Indian Biotechnology Sector Overview EBTC Business Plan 1 Indian Biotechnology Sector Overview Market Size and the Key Opportunity Segments The Indian biotechnology sector is one of the fastest growing

More information

Bayer Invests Heavily in R&D and is committed to innovation Sustained Innovation Output from all Subgroups

Bayer Invests Heavily in R&D and is committed to innovation Sustained Innovation Output from all Subgroups Open Innovation@BayerHealthCare Dr. Daniel Forler External Innovation Therapeutics Global Drug Discovery, Bayer HealthCare ASTP-Proton Conference Page 1 Bayer Invests Heavily in R&D and is committed to

More information

11º FORO MEDCAP R&D Medium Cap Leaders. Madrid, May 27, 2015

11º FORO MEDCAP R&D Medium Cap Leaders. Madrid, May 27, 2015 11º FORO MEDCAP R&D Medium Cap Leaders Madrid, May 27, 2015 01. A NEW COMPANY A NEW COMPANY Established: 2002 Spin-off from Natra Sector: Food supplements 2013 sales: 31.4 M 2013 EBITDA: 2.6 M Established:

More information

Overview of the EHR4CR project Electronic Health Record systems for Clinical Research

Overview of the EHR4CR project Electronic Health Record systems for Clinical Research Overview of the EHR4CR project Electronic Health Record systems for Clinical Research Dipak Kalra UCL on behalf of the EHR4CR Consortium ENCePP Plenary Meeting, 3rd May 2012, London The problem (as addressed

More information

Hong Kong Poised to be the Asia s Biotechnology Hub

Hong Kong Poised to be the Asia s Biotechnology Hub Think Asia, think Hong Kong - London 13-09-2011 www.hkbio.org.hk BioTech at Science Park Your Safe and Fast Track to China Hong Kong Poised to be the Asia s Biotechnology Hub Albert Cheung Hoi Yu, Ph.D.

More information

Key Findings. Use this report to... The Top 10 Contract Research Organizations

Key Findings. Use this report to... The Top 10 Contract Research Organizations Key Findings The global CRO industry valued $18bn in 2008, an increase of 14% over 2007. The CRO market will grow at an annual rate of 14% over the 2009 13 period. Quintiles leads the global CRO market

More information

Product Life Cycle Management in Life Sciences Industry

Product Life Cycle Management in Life Sciences Industry Life Cycle Management in Life Sciences Industry Evolving from siloed to cross-functional management Audit. Tax. Consulting. Corporate Finance. A need for Lifecycle Management Life Sciences companies are

More information

UNCOVERING OPPORTUNITIES IN THE BIOTECH SECTOR - BRAZIL

UNCOVERING OPPORTUNITIES IN THE BIOTECH SECTOR - BRAZIL UNCOVERING OPPORTUNITIES IN THE BIOTECH SECTOR - BRAZIL INTRODUCTION BY INNOVATION CENTRE DENMARK IN SAO PAULO BRAZILIAN BIOTECHNOLOGY SECTOR The Ministry of Science, Technology and Innovation (MCTI) considers

More information

Consumer Credit Worldwide at year end 2012

Consumer Credit Worldwide at year end 2012 Consumer Credit Worldwide at year end 2012 Introduction For the fifth consecutive year, Crédit Agricole Consumer Finance has published the Consumer Credit Overview, its yearly report on the international

More information

THE BIOTECH & PHARMACEUTICAL INDUSTRY

THE BIOTECH & PHARMACEUTICAL INDUSTRY THE BIOTECH & PHARMACEUTICAL INDUSTRY ESSENTIAL CAREERS INFORMATION CALUM LECKIE KATIE BISARO CAREERS CONSULTANTS What we will cover Sector overview Types of role Graduate recruitment trends and issues

More information

Executive Summary. Innovation in hydrogen fuel cells

Executive Summary. Innovation in hydrogen fuel cells EXECUTIVE SUMMARY 7 Executive Summary Innovation in energy technology has widespread implications for OECD economies. Although the energy sector accounts for a small share of GDP, the pervasive use of

More information

Career Opportunities in the Life Sciences

Career Opportunities in the Life Sciences Career Opportunities in Biotechnology and Drug Career Opportunities in the Life Sciences Toby Beth Freedman, Ph.D. February 28 th, 2008 1 The Experiment A comprehensive, systematic assessment of careers

More information

The Texas Biotechnology Industry

The Texas Biotechnology Industry The Texas Biotechnology Industry 2014 Fortune 1000 company NBTY opens state-of-the-art vitamin manufacturing plant in San Antonio See Page 15 Allergan installs new production line at Waco pharmaceutical

More information

The wine market: evolution and trends

The wine market: evolution and trends The wine market: evolution and trends May 2014 1 Table of contents 1. WINE CONSUMPTION 3 2. TRENDS IN WORLD WINE TRADE IN 20 6 3. TOP WINE EXPORTERS IN 20 7 4. TOP WINE IMPORTERS IN 20 9 5. THE FIVE LARGEST

More information

Profile of Biomedical Research and Biotechnology Commercialization. San Francisco Oakland San Jose Consolidated Metropolitan Statistical Area

Profile of Biomedical Research and Biotechnology Commercialization. San Francisco Oakland San Jose Consolidated Metropolitan Statistical Area Profile of Biomedical Research and Biotechnology Commercialization San Oakland San Jose Consolidated Metropolitan Statistical Area Overview and History of Biotechnology in San The San Bay area is in many

More information

OPEN INNOVATION STRATEGIES IN THE HEALTHCARE INDUSTRY

OPEN INNOVATION STRATEGIES IN THE HEALTHCARE INDUSTRY NINESIGMA WHITE PAPER OPEN INNOVATION STRATEGIES IN THE HEALTHCARE INDUSTRY How six leading healthcare companies are leveraging Open Innovation to achieve their innovation goals By: Stephen Clulow, Director

More information

U.S. Contract Research Outsourcing Market: Trends, Challenges and Competition in the New Decade. N8B7-52 December 2010

U.S. Contract Research Outsourcing Market: Trends, Challenges and Competition in the New Decade. N8B7-52 December 2010 U.S. Contract Research Outsourcing Market: Trends, Challenges and Competition in the New Decade December 2010 Table of Contents Notes on Methodology 8 Market Introduction and Segmentation Introduction

More information

INDUSTRY-ACADEMIC-CLINICAL FORUM

INDUSTRY-ACADEMIC-CLINICAL FORUM INDUSTRY-ACADEMIC-CLINICAL FORUM FUTURE TRENDS IN NANOMEDICINE FOR DIAGNOSTICS AND THERAPY IN ONCOLOGY Parc Científic de Barcelona / Barcelona Science Park 25 th of October of 2012 TABLE OF CONTENTS Agenda

More information

Ufficio Stampa Jacobacci & Partners

Ufficio Stampa Jacobacci & Partners Ufficio Stampa Jacobacci & Partners DATASTAMPA Simonetta Carbone Via Tiepolo, 10-10126 Torino, Italy Tel.: (+39) 011.19706371 Fax: (+39) 011.19706372 e-mail: piemonte@datastampa.it torino milano roma madrid

More information

BIOMEDICAL SCIENCES INDUSTRY IN SINGAPORE ROLE OF EDB

BIOMEDICAL SCIENCES INDUSTRY IN SINGAPORE ROLE OF EDB BIOMEDICAL SCIENCES INDUSTRY IN SINGAPORE ROLE OF EDB JAN 2014 1 Singapore s Economic Journey GDP (US$B) 260 240 220 200 180 160 140 120 100 80 60 40 20 0 1960-1969 Labour Intensive 1970 1979 Skill Intensive

More information

A targeted approach to infectious diseases and microbiology

A targeted approach to infectious diseases and microbiology What is a Technological Research Institute? A Technological Research Institute is an interdisciplinary institute bringing together industry and public research skills through medium-to long-term strategic

More information

Metropolitan Locations in International High-Tech Networks

Metropolitan Locations in International High-Tech Networks Metropolitan Locations in International High-Tech Networks Collaboration and Exchange of Creative Labour as a Basis for Advanced Socio-Economic Development 1 Contents 1. Localisation and Networking in

More information

The Sage Group and Talentmark Consulting Announce Strategic Alliance for Services to the Global Healthcare & Life Sciences Industry

The Sage Group and Talentmark Consulting Announce Strategic Alliance for Services to the Global Healthcare & Life Sciences Industry Talentmark Consulting Product Driven People Solutions Press Release The Sage Group and Talentmark Consulting Announce Strategic Alliance for Services to the Global Healthcare & Life Sciences Industry Cambridge

More information

HOT TOPICS IN IN HEALTH CARE REFORM

HOT TOPICS IN IN HEALTH CARE REFORM By Felicia Fuller Publications Manager, DAC Patient Recruitment Services The Patient Protection and Affordable Care Act (ACA), colloquially known as Obamacare, is in full effect and its impact is palpable

More information

Alianza 4 Universidades (Alliance A-4U) academic excellence, and technology & innovation

Alianza 4 Universidades (Alliance A-4U) academic excellence, and technology & innovation Alianza 4 Universidades (Alliance A-4U) At the forefront of research, academic excellence, and technology & innovation A strategic partnership of 4 leading Spanish public universities Universitat Autònoma

More information

Molecular Biotechnology Master s Degree Program

Molecular Biotechnology Master s Degree Program > APPLIED LIFE SCIENCES Master s Degree Program: > FULL TIME Molecular Biotechnology Master s Degree Program www.fh-campuswien.ac.at My Occupational Future. Your Career Opportunities Biotechnology is one

More information

Automating Cell Biology Annual general meeting, September 7, 2015. Phase Holographic Imaging www.phiab.se

Automating Cell Biology Annual general meeting, September 7, 2015. Phase Holographic Imaging www.phiab.se Automating Cell Biology Annual general meeting, September 7, 2015 www.phiab.se 1 PHASE HOLOGRAPHIC IMAGING (PHI) Began as a research project at Lund University, Sweden, in 2000 Founded in 2004 Sales in

More information

The Biomedical Industry and Medical Tourism in Singapore

The Biomedical Industry and Medical Tourism in Singapore The Biomedical Industry and Medical Tourism in Singapore Prof PHUA KAI HONG Health Policy and Management Lee Kuan Yew School of Public Policy National University of Singapore Introduction The Biomedical

More information

Press Release. iphex 2013 to showcase on Indian pharma exports; R & D capabilities

Press Release. iphex 2013 to showcase on Indian pharma exports; R & D capabilities Press Release iphex 2013 to showcase on Indian pharma exports; R & D capabilities Pharmexcil s iphex 2013 for global showcasing of Indian Pharma products Over 400 international buyers and regulators expected

More information

Introduction. The Healthcare Sector in Asia - Current Situation. Projected Healthcare Expenditure

Introduction. The Healthcare Sector in Asia - Current Situation. Projected Healthcare Expenditure Policy Issues in the Economics and Financing of Medical Technology in the Asia-Pacific Region Dr KAI HONG PHUA Joint Professor Yong Loo Lin School of Medicine and Lee Kuan Yew School of Public Policy National

More information

Pr. Dominique JOLLY SKEMA BS. Animatrice : Valérie BLANCHOT COURTOIS

Pr. Dominique JOLLY SKEMA BS. Animatrice : Valérie BLANCHOT COURTOIS Cycle Innovation & Connaissance 17 petit déjeuner Vendredi 14 février 2014 Comment les entreprises occidentales parient sur la création technologique en Chine? Du cost-driven au knowledge-driven Pr. Dominique

More information

Increasing Innovation in R&D - Seizing early stage external growth opportunities

Increasing Innovation in R&D - Seizing early stage external growth opportunities Increasing Innovation in R&D - Seizing early stage external growth opportunities Paul R. Eynott, PhD sanofi-aventis, US paul.eynott@sanofi-aventis.com -1- Sommaire -2- CHRISTOPHER A. VIEHBACHER Chief Executive

More information

Biosimilar Monoclonal Antibodies in the Pipeline: Major Players and Strategies

Biosimilar Monoclonal Antibodies in the Pipeline: Major Players and Strategies Biosimilar Monoclonal Antibodies in the Pipeline: Major Players and Strategies Fern Barkalow, Ph.D, Senior Analyst, Oncology Citeline One of the biggest challenges facing biosimilar drug developers is

More information

Normand Laberge Vice-President Regulatory & Scientific Affairs Rx&D. Globalization of Clinical Research: Trends & Implications for Canada

Normand Laberge Vice-President Regulatory & Scientific Affairs Rx&D. Globalization of Clinical Research: Trends & Implications for Canada Normand Laberge Vice-President Regulatory & Scientific Affairs Rx&D Globalization of Clinical Research: Trends & Implications for Success Rates by Phase and Therapeutic Area Source: Nature Reviews Drug

More information

Careers in the Pharmaceutical Industry - what really counts - Dr. Wolfgang Haupt Novartis Vaccines & Diagnostics, Marburg, Germany

Careers in the Pharmaceutical Industry - what really counts - Dr. Wolfgang Haupt Novartis Vaccines & Diagnostics, Marburg, Germany Careers in the Pharmaceutical Industry - what really counts - Dr. Wolfgang Haupt Novartis Vaccines & Diagnostics, Marburg, Germany Agenda Section 1 Overview on the Top Ten Pharmaceutical Companies Section

More information

The European Innovation Council A New Framework for EU Innovation Policy

The European Innovation Council A New Framework for EU Innovation Policy The European Innovation Council A New Framework for EU Innovation Policy EARTO recommendations to the European Commission to initiate further discussion 9 October 2015 Introduction: EIC as a Key Action

More information

Health Care Systems: Efficiency and Policy Settings

Health Care Systems: Efficiency and Policy Settings Health Care Systems: Efficiency and Policy Settings Summary in English People in OECD countries are healthier than ever before, as shown by longer life expectancy and lower mortality for diseases such

More information

Life Science - a sustainable platform for profitable growth

Life Science - a sustainable platform for profitable growth Life Science - a sustainable platform for profitable growth 2012 Life Science Information Day Bernd Reckmann Member of the Executive Board and Head of Chemicals Molsheim, France - December 5, 2012 Agenda

More information

The European Perspective

The European Perspective Back on Track Back on Track The European Perspective E UROPEAN INTRODUCTION Back on Track Europe s biotech industry is decisively back on track. After years of consolidation and relatively stagnant results,

More information

Special Feature: Growth Model of an Agile Company

Special Feature: Growth Model of an Agile Company Special Feature: Growth Model of an Agile Company 15 Sysmex s Global Strategy From the time of its establishment, Sysmex has followed a steady growth trajectory, and the Group now provides products and

More information

EXECUTIVE SUMMARY Prepared for: Pharmaceutical Research and Manufacturers of America (PhRMA) Prepared by: Battelle Technology Partnership Practice

EXECUTIVE SUMMARY Prepared for: Pharmaceutical Research and Manufacturers of America (PhRMA) Prepared by: Battelle Technology Partnership Practice EXECUTIVE SUMMARY Prepared for: Pharmaceutical Research and Manufacturers of America (PhRMA) Prepared by: Battelle Technology Partnership Practice Battelle is the world s largest non profit independent

More information

September 29, About BIO

September 29, About BIO The Comments of the Biotechnology Industry Organization on the Discussion Paper on Compulsory Licenses Published by the Department of Industrial Policy and Promotion within India's Ministry of Commerce

More information

Fit for Health 2.0 - International Strategy Development Training Innovative Business Solutions and Smart Financing

Fit for Health 2.0 - International Strategy Development Training Innovative Business Solutions and Smart Financing Fit for Health 2.0 - International Strategy Development Training Innovative Business Solutions and Smart Financing Thursday 08 October 2015 8-9 October 2015, Copenhagen (Denmark) Medicon Valley Alliance,

More information

Biotechnology in Canada - A Regional View. February 2004 Life Sciences Branch Industry Canada

Biotechnology in Canada - A Regional View. February 2004 Life Sciences Branch Industry Canada Biotechnology in Canada - A Regional View February 2004 Life Sciences Branch Industry Canada Objective and Contents Objective: This presentation compares key biotechnology statistics across Canadian regions

More information

Commercial Insight: Cancer Targeted Therapies and Immunotherapies -Top monoclonal antibody brands will resist competitive pressures through to 2019

Commercial Insight: Cancer Targeted Therapies and Immunotherapies -Top monoclonal antibody brands will resist competitive pressures through to 2019 Brochure More information from http://www.researchandmarkets.com/reports/1314569/ Commercial Insight: Cancer Targeted Therapies and Immunotherapies -Top monoclonal antibody brands will resist competitive

More information

MSD Information Technology Global Innovation Center. Digitization and Health Information Transparency

MSD Information Technology Global Innovation Center. Digitization and Health Information Transparency MSD Information Technology Global Innovation Center Digitization and Health Information Transparency 10 February 2014 1 We are seeking energetic, forward thinking graduates to join our Information Technology

More information

Shifting paths of pharmaceutical innovation: Implications for the global pharmaceutical industry

Shifting paths of pharmaceutical innovation: Implications for the global pharmaceutical industry Shifting paths of pharmaceutical innovation: Implications for the global pharmaceutical industry Tariq Sadat PhD Candidate School of Economics, Finance and Marketing, RMIT University, Australia Roslyn

More information

Australia: Current Position and Key Success Factors

Australia: Current Position and Key Success Factors Competitive Positioning Strategies for Australian Biotech Companies A Road Map to Achieve Competitive Position in the Global Biotech Marketplace Part III Australia: Current Position and Key Success Factors

More information

Rio de Janeiro, Dec 10 th., 2015

Rio de Janeiro, Dec 10 th., 2015 Rio de Janeiro, Dec 10 th., 2015 Brazil & The Netherlands - 59% of Dutch import from Latin-America comes from Brazil; - 47% of Dutch total export to Latin-America goes to Brazil - The Netherlands 4 th

More information

A BIOMEDICAL CLUSTER 15 years in the making. October 9, 2015

A BIOMEDICAL CLUSTER 15 years in the making. October 9, 2015 A BIOMEDICAL CLUSTER 15 years in the making October 9, 2015 1 Agenda Innovation Pipeline Case Studies Our Case Conclusion 2 Key: Build Innovation Pipeline Deliver Knowledge to Market Discover Develop Deploy

More information

Can India be the Leader in Global Generics. Rtn. J. Jayaseelan.,B.Pharm., M.B.A., Managing Director

Can India be the Leader in Global Generics. Rtn. J. Jayaseelan.,B.Pharm., M.B.A., Managing Director Can India be the Leader in Global Generics Rtn. J. Jayaseelan.,B.Pharm., M.B.A., Managing Director Indian Pharma Industry Before 1970 Depending on MNC from USA and Europe for supply of Medicines Hardly

More information

A Texas Life Science Perspective. Thomas R. Kowalski President Texas Healthcare and Bioscience Institute

A Texas Life Science Perspective. Thomas R. Kowalski President Texas Healthcare and Bioscience Institute A Texas Life Science Perspective Thomas R. Kowalski President Texas Healthcare and Bioscience Institute 1 What is THBI? The Texas Healthcare and Bioscience Institute (THBI) is a non-profit, public policy

More information

Legislative Council Secretariat FACT SHEET. Pharmaceutical industry in Denmark

Legislative Council Secretariat FACT SHEET. Pharmaceutical industry in Denmark FACT SHEET Pharmaceutical industry in Denmark 1. Introduction 1.1 The Danish pharmaceutical industry is known worldwide for providing quality drugs and medical products. In 2012, Denmark was the 16 th

More information

Biomedical Accelerator Fund. Office of Technology Development Harvard University

Biomedical Accelerator Fund. Office of Technology Development Harvard University Biomedical Accelerator Fund Office of Technology Development Harvard University Curtis Keith, Chief Scientific Officer May 21, 2012 Mission of Harvard s Office 2 Organizational Structure of Harvard OTD

More information

Biological Technicians

Biological Technicians SOC 19-4021: Assist biological and medical scientists in laboratories. Set up, operate, and maintain laboratory instruments and equipment, monitor experiments, make observations, and calculate and record

More information

Strength and Opportunity. The landscape of the medical technology, medical biotechnology and industrial biotechnology sectors in the UK

Strength and Opportunity. The landscape of the medical technology, medical biotechnology and industrial biotechnology sectors in the UK Strength and Opportunity The landscape of the medical technology, medical biotechnology and industrial biotechnology sectors in the UK Annual Update December 2010 Cover photo is from the UKTI Life Sciences

More information

Roche R&D Center China (RRDCC) Media Visit to Roche in China Shanghai 30 October 2005 Andreas Tschirky, Ph.D. Head of Roche R&D Center (China) Ltd.

Roche R&D Center China (RRDCC) Media Visit to Roche in China Shanghai 30 October 2005 Andreas Tschirky, Ph.D. Head of Roche R&D Center (China) Ltd. Roche R&D Center China (RRDCC) Media Visit to Roche in China Shanghai 30 October 2005 Andreas Tschirky, Ph.D. Head of Roche R&D Center (China) Ltd. Roche recognizes changes in China Strong economic development

More information

Marieme Ba for CAAST-NET + 1 st stakeholder meeting Entebbe November 2014

Marieme Ba for CAAST-NET + 1 st stakeholder meeting Entebbe November 2014 Coming together is a beginning, keeping together is progress, working together is success. - Henry Ford - Considering the clinical research industry as an area for enhanced public-private sector collaboration

More information

Translational research infrastructure in Neurosciences 15.06.2011/Bruxelles

Translational research infrastructure in Neurosciences 15.06.2011/Bruxelles ITMO Neurosciences, sciences cognitives, neurologie, psychiatrie Translational research infrastructure in Neurosciences 15.06.2011/Bruxelles ITMO Technologie pour la santé 1 NEUROSCIENCE MEDICAL CHALLENGES

More information

BioTuesday Introduction to Kendle. Philippe Moreau, CRA Manager

BioTuesday Introduction to Kendle. Philippe Moreau, CRA Manager BioTuesday Introduction to Kendle Philippe Moreau, CRA Manager March 1, 2011 Overview Top-tier CRO uniquely positioned to deliver Phases I-IV 30-year track record of delivering on client expectations Partners

More information

BioMed Partners. The rocky way from science to market. Dr. Karsten Fischer BioMedPartners AG. VPM Days Hannover

BioMed Partners. The rocky way from science to market. Dr. Karsten Fischer BioMedPartners AG. VPM Days Hannover The rocky way from science to market Dr. Karsten Fischer BioMedPartners AG VPM Days Hannover November 2013 Content I. Stage 1 II. Setbacks 6 III. Hope 12 IV. Solutions 17 V. Expertise 20 Page 1 The Challenge

More information

Corporate Presentation

Corporate Presentation Corporate Presentation Introduction Farmantra is a consulting company specialized in life sciences industry with an initiative to address the gaps in the value chains due to the changing business models

More information

Most countries will experience an increase in pharmaceutical spending per capita by 2018

Most countries will experience an increase in pharmaceutical spending per capita by 2018 6 Most countries will experience an increase in pharmaceutical spending per capita by 218 Pharmaceutical spending per capita, 213 versus 218 1,6 1,4 Pharmaceutical Spend per Capita 1,2 1, 8 6 4 2 US Japan

More information

1. What are the key strengths and weaknesses of the UK s innovation system in relation to business-university collaboration?

1. What are the key strengths and weaknesses of the UK s innovation system in relation to business-university collaboration? ABPI S RESPONSE TO THE BUSINESS, INNOVATION AND SKILLS SELECT COMMITTEE INQUIRY INTO THE STRENGTHS AND WEAKNESSES OF BUSINESS-UNIVERSITY COLLABORATION IN THE UK AND THE UK S PERFORMANCE AGAINST INTERNATIONAL

More information

Pivot Park Screening Centre participates in novel 196 million pan-european drug discovery platform

Pivot Park Screening Centre participates in novel 196 million pan-european drug discovery platform PRESS RELEASE Pivot Park Screening Centre participates in novel 196 million pan-european drug discovery platform Pivot Park Screening Centre in Oss will play an important role in a new pan-european drug

More information

Public funding policies: which options for small innovative companies in 2009. Biotech SMEs in the EU: how to improve access to finance

Public funding policies: which options for small innovative companies in 2009. Biotech SMEs in the EU: how to improve access to finance Public funding policies: which options for small innovative companies in 2009 Biotech SMEs in the EU: how to improve access to finance Dirk Carrez Director, EuropaBio EuroBio - 25 September 2009 (Lille)

More information

What Lies Ahead? Trends to Watch: Health Care Product Development in North America

What Lies Ahead? Trends to Watch: Health Care Product Development in North America What Lies Ahead? Trends to Watch: Health Care Product Development in North America What Lies Ahead? for 2015 DIA has released its third annual What Lies Ahead? report, providing experts insights into the

More information

Pennino Corporation TECHNOLOGY TO IMPROVE LIFE

Pennino Corporation TECHNOLOGY TO IMPROVE LIFE Pennino Corporation TECHNOLOGY TO IMPROVE LIFE Agenda The Opportunity Highlights Corporate Profile NYU Relationship Obesity and Diabetes Graphics and Facts Next Stage of Development Efficacy and Safety

More information

2009 Foley & Lardner LLP Attorney Advertising Prior results do not guarantee a similar outcome Models used are not clients but may be representative

2009 Foley & Lardner LLP Attorney Advertising Prior results do not guarantee a similar outcome Models used are not clients but may be representative Attorney Advertising Prior results do not guarantee a similar outcome Models used are not clients but may be representative of clients 321 N. Clark Street, Suite 2800, Chicago, IL 60654 312.832.4500 Life

More information

Life Sciences Outlook. Greater Toronto Area Fall 2015

Life Sciences Outlook. Greater Toronto Area Fall 2015 Life Sciences Outlook Greater Toronto Area Fall 2015 Greater Toronto Toronto is one of North America's largest life sciences sectors and is ranked as one of the top 10 biomedical sectors in the world.

More information

Medium-term Business Plan

Medium-term Business Plan Mitsubishi UFJ Financial Group, Inc. Medium-term Business Plan Tokyo, May 15, 2015 --- Mitsubishi UFJ Financial Group, Inc. (MUFG) announced today that it has formulated its medium-term business plan for

More information

This is GE Healthcare

This is GE Healthcare This is GE Healthcare An Overview Imagination at work Last updated July 2014 General Electric: A heritage of innovation Founded by Thomas Edison in 1878 Only company from the original 1896 Dow Jones index

More information

GAO NEW DRUG DEVELOPMENT. Science, Business, Regulatory, and Intellectual Property Issues Cited as Hampering Drug Development Efforts

GAO NEW DRUG DEVELOPMENT. Science, Business, Regulatory, and Intellectual Property Issues Cited as Hampering Drug Development Efforts GAO United States Government Accountability Office Report to Congressional Requesters November 2006 NEW DRUG DEVELOPMENT Science, Business, Regulatory, and Intellectual Property Issues Cited as Hampering

More information

GE Global Innovation Barometer

GE Global Innovation Barometer GE Global Innovation Barometer 2013 Results Focus Turkey 1 Copyright 2012 Daniel J Edelman Inc. GE global innovation barometer methodology Now in its third edition and spanning across 25 countries, the

More information

Investing in the United States Tazeem Pasha

Investing in the United States Tazeem Pasha Investing in the United States Tazeem Pasha Embassy of Spain and ICEX Seminar on Financing Opportunities forspanish Companies and Projects in the United States By Tazeem Pasha Monday, 19 March 2012 Washington,

More information

Ipsos / Europ Assistance barometer Europeans Plans and Concerns for the Holidays Summary Ipsos for the Europ Assistance Group May 24th 2012

Ipsos / Europ Assistance barometer Europeans Plans and Concerns for the Holidays Summary Ipsos for the Europ Assistance Group May 24th 2012 Ipsos / Europ Assistance barometer Europeans Plans and Concerns for the Holidays Summary Ipsos for the Europ Assistance Group May 24th 2012 Contacts Ipsos Public Affairs: Fabienne SIMON 01 41 98 92 15

More information

Chapter 2. Education and Human Resource Development for Science and Technology

Chapter 2. Education and Human Resource Development for Science and Technology Chapter 2 Education and Human Resource Development for Science and Technology 2.1 Evironment for Basic Human Resource Development... 53 2.1.1 Science education in primary and secondary schools... 53 2.1.2

More information

Achievement of Korea s Healthcare Industry. Devices. World s largest market share in ultrasound imaging devices ( 14) Competitiveness

Achievement of Korea s Healthcare Industry. Devices. World s largest market share in ultrasound imaging devices ( 14) Competitiveness 2015 Healthcare Healthcare Korea's healthcare industry is growing thanks to the advancement of the production infrastructure of pharmaceuticals, medical devices and cosmetics, support for healthcare-related

More information

Instruments to control and finance the building of healthcare infrastructure in other countries of the European Union

Instruments to control and finance the building of healthcare infrastructure in other countries of the European Union Summary and conclusions This report describes the instruments by which the respective authorities of eight important European Union members control the building, financing and geographical distribution

More information

Australia Life Sciences Market

Australia Life Sciences Market Australia Life Sciences Market Monique Roos, Commercial Specialist U.S. Commercial Service, Sydney, Australia November 2014 Geographical Size Population Density More than 80% of population in this ring

More information

Research and Development in the Czech Republic. Mr. Jiri Krechl Head of R&D Support Department

Research and Development in the Czech Republic. Mr. Jiri Krechl Head of R&D Support Department Research and Development in the Czech Republic Mr. Jiri Krechl Head of R&D Support Department CZECHINVEST Investment and Business Development Agency Ministry of Industry and Trade CzechInvest Investment

More information

Job Profile Clinical Research Associate I/II (CRA)

Job Profile Clinical Research Associate I/II (CRA) PART 1 - PROFILE You are an experienced CRA with a strong background in Clinical Research who is passionate about drug development and are seeking a challenging and rewarding career in a quality focussed

More information

Backgrounder. Australian businesses as investors in research and development. December 2014. page 1

Backgrounder. Australian businesses as investors in research and development. December 2014. page 1 Backgrounder Australian businesses as investors in research and development December 2014 page 1 Backgrounder Australian businesses as investors in research and development Executive summary Australia

More information

Profile of Biomedical Research and Biotechnology Commercialization. Boston-Worcester-Lawrence Consolidated Metropolitan Statistical Area

Profile of Biomedical Research and Biotechnology Commercialization. Boston-Worcester-Lawrence Consolidated Metropolitan Statistical Area Profile of Biomedical Research and Biotechnology Commercialization Boston-Worcester-Lawrence Consolidated Metropolitan Statistical Area Overview and History of Biotechnology in Boston Along with San Francisco,

More information

China Pharma Holdings, Inc. Reports Second Quarter 2010 Financial Results

China Pharma Holdings, Inc. Reports Second Quarter 2010 Financial Results China Pharma Holdings, Inc. Reports Second Quarter 2010 Financial Results HAIKOU CITY, China, August 10, 2010 China Pharma Holdings, Inc. (NYSE AMEX: CPHI) ( China Pharma or the Company ), a leading fully

More information

Trends in Innovation in Middle Income Countries: The Case of Biotechnology

Trends in Innovation in Middle Income Countries: The Case of Biotechnology Trends in Innovation in Middle Income Countries: The Case of Biotechnology Joseph Damond, Senior Vice President, International Affairs, Biotechnology Industry Organization INNOVATION AND ACCESS TO MEDICAL

More information

THE ITALIAN MACHINE TOOLS, ROBOTS AND AUTOMATION SYSTEMS MANUFACTURING INDUSTRY 2

THE ITALIAN MACHINE TOOLS, ROBOTS AND AUTOMATION SYSTEMS MANUFACTURING INDUSTRY 2 THE ITALIAN MACHINE TOOLS, ROBOTS AND AUTOMATION SYSTEMS MANUFACTURING INDUSTRY 2 THE DATA OF 2014 2 EXPORTS 3 STRUCTURAL CHARACTERISTICS 6 Machine tools 6 Robotics 7 THE WORLD MACHINE TOOL INDUSTRY 8

More information

Dear Business Development or Corporate Alliance Director/Manager,

Dear Business Development or Corporate Alliance Director/Manager, Korea Drug Research Association(KDRA) and Korea Health Industry Development Institute(KHIDI) cordially request the potential global outsourcing partners(cros, CMOs, CSOs & Consulting Firms) having contract

More information

EUROPEAN AMERICAN ENTERPRISE COUNCIL

EUROPEAN AMERICAN ENTERPRISE COUNCIL information guide 2012 PROMOTING PARTICIPATION AND CONTRIBUTION PROMOTING COLLABORATION AND TRUST FOSTERING ENTREPRENEURSH IP AND TRADE FOSTERING INNOVATION AND INTEGRATION 01 Acceleration and Business

More information

Providing High-Quality Innovation and Technology Support Services University Experience and Best Practices. Professor Stanley Kowalski

Providing High-Quality Innovation and Technology Support Services University Experience and Best Practices. Professor Stanley Kowalski Providing High-Quality Innovation and Technology Support Services University Experience and Best Practices Professor Stanley Kowalski Overview: Technology Transfer Defined Mission and Policy Statutory

More information

Stephen Dibert Global Practice Lead Life Sciences Foreign Affairs, Trade and Development Canada JBA Seminar - February, 2015

Stephen Dibert Global Practice Lead Life Sciences Foreign Affairs, Trade and Development Canada JBA Seminar - February, 2015 Life Sciences Industry in Canada Stephen Dibert Global Practice Lead Life Sciences Foreign Affairs, Trade and Development Canada JBA Seminar - February, 2015 Life Sciences in Canada Canadian life sciences

More information

President and CEO. Research Park Corporation. Baton Rouge, Louisiana

President and CEO. Research Park Corporation. Baton Rouge, Louisiana July 2014 President and CEO Research Park Corporation Baton Rouge, Louisiana Introduction The Research Park Corporation (RPC) was established as a public, nonprofit corporation in 1992 by the Louisiana

More information

Life Sciences and Biotechnology: The Transatlantic Divide

Life Sciences and Biotechnology: The Transatlantic Divide Life sciences and biotechnology 1 have seen a rapid expansion over the last few years. Scientific advances in genetics and molecular biology and their combination with chemical engineering and new information

More information

Statistics Compendium EBAN 2014. 5.5b

Statistics Compendium EBAN 2014. 5.5b Statistics Compendium EBAN 2014 5.5b The Statistics Compendium is Europe s most extensive annual research on the activity of business angels and business angel networks. It provides information on the

More information

The Global Biotech Industry: Challenges & Opportunities Michael S. Rosen Rosen Bioscience Strategies

The Global Biotech Industry: Challenges & Opportunities Michael S. Rosen Rosen Bioscience Strategies The Global Biotech Industry: Challenges & Opportunities Michael S. Rosen Rosen Bioscience Strategies Greetings from Chicago! Beaches Yes! Pharma Beginnings! Bogota 1974 Selling Drugs in Colombia Global

More information

Insurance corporations and pension funds in OECD countries

Insurance corporations and pension funds in OECD countries Insurance corporations and pension funds in OECD countries Massimo COLETTA (Bank of Italy) Belén ZINNI (OECD) UNECE, Expert Group on National Accounts, Geneva - 3 May 2012 Outline Motivations Insurance

More information